Hiroshi Kuriki

2.8k total citations
34 papers, 852 citations indexed

About

Hiroshi Kuriki is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Surgery. According to data from OpenAlex, Hiroshi Kuriki has authored 34 papers receiving a total of 852 indexed citations (citations by other indexed papers that have themselves been cited), including 19 papers in Oncology, 16 papers in Pulmonary and Respiratory Medicine and 8 papers in Surgery. Recurrent topics in Hiroshi Kuriki's work include Lung Cancer Treatments and Mutations (12 papers), Cancer Immunotherapy and Biomarkers (8 papers) and Colorectal Cancer Treatments and Studies (6 papers). Hiroshi Kuriki is often cited by papers focused on Lung Cancer Treatments and Mutations (12 papers), Cancer Immunotherapy and Biomarkers (8 papers) and Colorectal Cancer Treatments and Studies (6 papers). Hiroshi Kuriki collaborates with scholars based in Japan, United States and Italy. Hiroshi Kuriki's co-authors include David R. Spigel, Shonen Yoshida, Jacek Jassem, Filippo de Marinis, Simonetta Mocci, Roy S. Herbst, Kazuhiko Nakagawa, Tomohide Tamura, Makoto Nishio and Ida Enquist and has published in prestigious journals such as Journal of Clinical Oncology, Blood and PLoS ONE.

In The Last Decade

Hiroshi Kuriki

32 papers receiving 839 citations

Peers

Countries citing papers authored by Hiroshi Kuriki

Since Specialization

Citations

This map shows the geographic impact of Hiroshi Kuriki's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Hiroshi Kuriki with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Hiroshi Kuriki more than expected).

Fields of papers citing papers by Hiroshi Kuriki

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Hiroshi Kuriki. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Hiroshi Kuriki. The network helps show where Hiroshi Kuriki may publish in the future.

Co-authorship network of co-authors of Hiroshi Kuriki

This figure shows the co-authorship network connecting the top 25 collaborators of Hiroshi Kuriki. A scholar is included among the top collaborators of Hiroshi Kuriki based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Hiroshi Kuriki. Hiroshi Kuriki is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Updated Overall Survival Analysis From IMpower110: Atezolizumab Versus Platinum-Based Chemotherapy in Treatment-Naive Programmed Death-Ligand 1–Selected NSCLC 2021 ·Journal of Thoracic Oncology ·Jacek Jassem, Filippo de Marinis, Giuseppe Giaccone, A. Vergnenègre, Carlos H. Barrios, Masahiro Morise, Enriqueta Felip, Cristina Oprean, Young‐Chul Kim, Zoran Andrić, Simonetta Mocci, Ida Enquist, Kimberly M. Komatsubara, Mark L. McCleland, Hiroshi Kuriki, (unknown), See Phan, David R. Spigel, Roy S. Herbst	114
2	Incorporating Unstructured Patient Narratives and Health Insurance Claims Data in Pharmacovigilance: Natural Language Processing Analysis of Patient-Generated Texts About Systemic Lupus Erythematosus 2021 ·JMIR Public Health and Surveillance ·Shinichi Matsuda, (unknown), (unknown), (unknown), (unknown), Hiroshi Kuriki, (unknown), (unknown)	4
3	1190TiP SKYSCRAPER-03: Phase III, open-label randomised study of atezolizumab + tiragolumab vs durvalumab in patients with locally advanced, unresectable, stage III non-small cell lung cancer (NSCLC) who have not progressed after platinum-based concurrent chemoradiation (cCRT) 2021 ·Annals of Oncology ·Rafał Dziadziuszko, M-J. Ahn, K. A. Kelly, Sanjay Popat, Heather A. Wakelee, (unknown), Isabelle Rooney, (unknown), (unknown), (unknown), Hiroshi Kuriki, Namrata S. Patil, Xin Wen, Jeffrey D. Bradley	6
4	FP13.03 IMpower110: Updated OS Analysis of Atezolizumab vs Platinum-Based Chemotherapy as First-Line Treatment in PD-L1–Selected NSCLC 2021 ·Journal of Thoracic Oncology ·Roy S. Herbst, Filippo de Marinis, Giuseppe Giaccone, A. Vergnenègre, Carlos H. Barrios, Masahiro Morise, Enriqueta Felip, Cristina Oprean, (unknown), Zoran Andrić, Simonetta Mocci, Ida Enquist, (unknown), Mark L. McCleland, Yu Deng, Hiroshi Kuriki, Matthias Villalobos, S. Phan, David R. Spigel, Jacek Jassem	8
5	O81 IMpower110: interim overall survival (OS) analysis of a phase III study of atezolizumab (ATEZO) monotherapy vs platinum-based chemotherapy (CHEMO) as first-line (1L) treatment in PD-L1–selected NSCLC 2020 ·Oral Presentations ·Roy S. Herbst, Filippo de Marinis, Giuseppe Giaccone, Niels Reinmuth, A. Vergnenègre, Carlos H. Barrios, Masahiro Morise, E. Felip Font, Zoran Andrić, Sarayut Lucien Geater, Mustafa Özgüroğlu, Simonetta Mocci, Mark L. McCleland, Ida Enquist, (unknown), Yu Deng, Hiroshi Kuriki, Xiaohui Wen, Jacek Jassem, David R. Spigel	6
6	Patient-reported outcomes (PROs) in the randomized, phase III IMpower110 study of atezolizumab (atezo) vs chemotherapy in 1L metastatic NSCLC. 2020 ·Journal of Clinical Oncology ·Filippo de Marinis, Giuseppe Giaccone, Roy S. Herbst, Cristina Oprean, Aleksandra Szczęsna, Ioannis Boukovinas, Lucia Bonomi, Young‐Chul Kim, Yvonne Summers, Takayasu Kurata, Kimberly M. Komatsubara, (unknown), Yu Deng, Hiroshi Kuriki, Simonetta Mocci, See Phan, Jacek Jassem, David R. Spigel	4
7	IMpower110: Clinical safety in a phase III study of atezolizumab (atezo) monotherapy (mono) vs platinum-based chemotherapy (chemo) in first-line non-small cell lung cancer (NSCLC). 2020 ·Journal of Clinical Oncology ·Jacek Jassem, Roy S. Herbst, Filippo de Marinis, Jacquès Cadranel, Tibor Csőszi, Dolores Isla, Gongyan Chen, Konstantinos N. Syrigos, Diego Cortinovis, Toyoaki Hida, Simonetta Mocci, See Phan, Ida Enquist, Hina Patel, (unknown), Xiaohui Wen, Yu Deng, Hiroshi Kuriki, David R. Spigel, Giuseppe Giaccone	11
8	Analysis of central nervous system efficacy in the J-ALEX study of alectinib versus crizotinib in ALK-positive non-small-cell lung cancer 2018 ·Lung Cancer ·Makoto Nishio, Kazuhiko Nakagawa, Tetsuya Mitsudomi, Nobuyuki Yamamoto, Tomohiro Tanaka, Hiroshi Kuriki, Ali Zeaiter, Tomohide Tamura	57
9	MA07.03 Alectinib (ALC) versus Crizotinib (CRZ) in ALK-Positive Non-Small Cell Lung Cancer (ALK+ NSCLC): Primary Results from Phase III Study (J-ALEX) 2017 ·Journal of Thoracic Oncology ·Young Kim, Toyoaki Hida, Hiroshi Nokihara, Masashi Kondo, Koichi Azuma, Takashi Seto, Yuichi Takiguchi, Makoto Nishio, Hiroshige Yoshioka, Fumio Imamura, Katsuyuki Hotta, Satoshi Watanabe, Kōichi Goto, Kazuhiko Nakagawa, Tetsuya Mitsudomi, Nobuyuki Yamamoto, Hiroshi Kuriki, (unknown), Tomohiro Tanaka, Tomohide Tamura	4
10	Analysis of Patient Narratives in Disease Blogs on the Internet: An Exploratory Study of Social Pharmacovigilance 2017 ·JMIR Public Health and Surveillance ·Shinichi Matsuda, (unknown), (unknown), (unknown), (unknown), Hiroshi Kuriki, Yōichirō Takahashi	22
11	Regional differences in advanced gastric cancer: exploratory analyses of the AVAGAST placebo arm 2017 ·Gastric Cancer ·Akira Sawaki, Yasuhide Yamada, Kensei Yamaguchi, Tomohiro Nishina, Toshihiko Doi, Taroh Satoh, Keisho Chìn, Narikazu Boku, Yasushi Omuro, Yoshito Komatsu, Yasuo Hamamoto, Wasaburo Koizumi, Shigehira Saji, Manish A. Shah, Eric Van Cutsem, Yoon‐Koo Kang, (unknown), Hiroshi Kuriki, (unknown), Atsushi Ohtsu	23
12	Three-Year Follow-Up of an Alectinib Phase I/II Study in ALK-Positive Non–Small-Cell Lung Cancer: AF-001JP 2017 ·Journal of Clinical Oncology ·Tomohide Tamura, Katsuyuki Kiura, Takashi Seto, Kazuhiko Nakagawa, Makoto Maemondo, Akira Inoue, Toyoaki Hida, Hiroshige Yoshioka, Masao Harada, Yuichiro Ohe, Naoyuki Nogami, Haruyasu Murakami, Hiroshi Kuriki, Tadashi Shimada, Tomohiro Tanaka, Kengo Takeuchi, Makoto Nishio	52
13	Adjuvant capecitabine plus oxaliplatin after D2 gastrectomy in Japanese patients with gastric cancer: a phase II study 2016 ·Gastric Cancer ·Nozomu Fuse, Hideaki Bando, Keisho Chìn, Seiji Ito, Takaki Yoshikawa, Akira Tsuburaya, Masanori Terashima, Yoshiyuki Kawashima, Tetsu Fukunaga, Masahiro Gotoh, Yasunori Emi, Kazuhiro Yoshida, Eiji Oki, (unknown), Hiroshi Kuriki, Kumi Sato, Mitsuru Sasako	60
14	Bias in Spontaneous Reporting of Adverse Drug Reactions in Japan 2015 ·PLoS ONE ·Shinichi Matsuda, (unknown), (unknown), (unknown), T Kobayashi, Hiroshi Kuriki, (unknown), (unknown), (unknown), (unknown), Yōichirō Takahashi	39
15	Interpretation of HER2 tests in gastric cancer: confirmation of interobserver differences and validation of a QA/QC educational program 2014 ·Archiv für Pathologische Anatomie und Physiologie und für Klinische Medicin ·Ryoji Kushima, Takeshi Kuwata, Takashi Yao, Hiroshi Kuriki, Kaoru Hashizume, Shinobu Masuda, Hitoshi Tsuda, Atsushi Ochiai	12
16	A Case of Congenital Cystic Dilatation of Bile Duct without Pancreaticobiliary Maljunction. 1999 ·The Japanese Journal of Gastroenterological Surgery ·(unknown), (unknown), Hiroshi Kuriki, Kenji Sakaguchi, Eiji Hayashi	0
17	Existence of Phosphoinositide-Specific Phospholipase C in Rat Liver Nuclei and Its Change during Liver Regeneration1 1992 ·The Journal of Biochemistry ·Hiroshi Kuriki, Keiko Tamiya‐Koizumi, (unknown), Shonen Yoshida, Kiyohide Kojima, Yuji Nimura	46
18	Decrease in Regeneration Capacity of Rat Liver after External Biliary Drainage 1992 ·European Surgical Research ·Shinsuke Iyomasa, (unknown), Hiroshi Kuriki, Y Nimura, Shigehiko Shionoya, (unknown), (unknown)	27
19	Induction of DNA Replication and Cell Growth in Rat Liver by Obstructive Jaundice 1991 ·Japanese Journal of Cancer Research ·(unknown), Hiroshi Kuriki, Yuji Nimura, Shigehiko Shionoya, Kiyohide Kojima, Shonen Yoshida	13
20	Growth-associated changes in fatty acid compositions of nuclear phospholipids of liver cells 1991 ·Biochimica et Biophysica Acta (BBA) - Lipids and Lipid Metabolism ·(unknown), Keiko Tamiya‐Koizumi, Hiroshi Kuriki, Shonen Yoshida, (unknown)	19

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact